Chimeric antigen receptor-modified T cells strike back

od Frigault, Matthew J., Maus, Marcela V.
Wydane w Int Immunol (2016)

State of the art in CAR T cell therapy for CD19(+) B cell malignancies

od Frigault, Matthew J., Maus, Marcela V.
Wydane w J Clin Invest (2020)

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy

od Bedoya, Felipe, Frigault, Matthew J., Maus, Marcela V.
Wydane w Mol Ther (2017)

CAR-Based Approaches to Cutaneous T-Cell Lymphoma

od Scarfò, Irene, Frigault, Matthew J., Maus, Marcela V.
Wydane w Front Oncol (2019)

Clinical Perspective: Treatment of Aggressive B Cell Lymphomas with FDA-Approved CAR-T Cell Therapies

od Leick, Mark B., Maus, Marcela V., Frigault, Matthew J.
Wydane w Mol Ther (2021)

CARs in the lead against Multiple Myeloma

od Ormhøj, Maria, Bedoya, Felipe, Frigault, Matthew J., Maus, Marcela V.
Wydane w Curr Hematol Malig Rep (2017)

Immunomodulation as Treatment for Severe Coronavirus Disease 2019: A Systematic Review of Current Modalities and Future Directions

od Meyerowitz, Eric A, Sen, Pritha, Schoenfeld, Sara R, Neilan, Tomas G, Frigault, Matthew J, Stone, John H, Kim, Arthur Y, Mansour, Michael K
Wydane w Clin Infect Dis (2020)

ICOS-based chimeric antigen receptors program bipolar T(H)17/T(H)1 cells

od Guedan, Sonia, Chen, Xi, Madar, Aviv, Carpenito, Carmine, McGettigan, Shannon E., Frigault, Matthew J., Lee, Jihyun, Posey, Avery D., Scholler, John, Scholler, Nathalie, Bonneau, Richard, June, Carl H.
Wydane 2014

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

od Frigault, Matthew J., Nikiforow, Sarah, Mansour, Michael K., Hu, Zhen-Huan, Horowitz, Mary M., Riches, Marcie L., Hematti, Peiman, Turtle, Cameron J., Zhang, Mei-Jie, Perales, Miguel-Angel, Pasquini, Marcelo C.
Wydane w Blood (2020)

Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma

od Gupta, Shruti, Seethapathy, Harish, Strohbehn, Ian A., Frigault, Matthew J., O’Donnell, Elizabeth K., Jacobson, Caron A., Motwani, Shveta S., Parikh, Samir M., Curhan, Gary C., Reynolds, Kerry L., Leaf, David E., Sise, Meghan E.
Wydane w Am J Kidney Dis (2020)

Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma

od Trujillo, Jonathan A., Godfrey, James, Hu, Yifei, Huang, Jun, Smith, Sonali M., Frigault, Matthew J., DeFilipp, Zachariah, Appelbaum, Daniel, Pu, Yonglin, Feinberg, Nicholas, Althaus, Thomas, Bishop, Michael R., Riedell, Peter A., Kline, Justin
Wydane w Blood (2021)

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas

od Scarfò, Irene, Ormhøj, Maria, Frigault, Matthew J., Castano, Ana P., Lorrey, Selena, Bouffard, Amanda A., van Scoyk, Alexandria, Rodig, Scott J., Shay, Alexandra J., Aster, Jon C., Preffer, Frederic I., Weinstock, David M., Maus, Marcela V.
Wydane w Blood (2018)

Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma

od Frigault, Matthew J., Dietrich, Jorg, Martinez-Lage, Maria, Leick, Mark, Choi, Bryan D., DeFilipp, Zachariah, Chen, Yi-Bin, Abramson, Jeremy, Crombie, Jennifer, Armand, Philippe, Nayak, Lakshmi, Panzini, Chris, Riley, Lauren S., Gallagher, Kathleen, Maus, Marcela V.
Wydane w Blood (2019)

Clinical response to larotrectinib in adult Philadelphia chromosome–like ALL with cryptic ETV6-NTRK3 rearrangement

od Nardi, Valentina, Ku, Nora, Frigault, Matthew J., Dubuc, Adrian M., Tsai, Harrison Kwei, Amrein, Philip C., Hobbs, Gabriela S., Brunner, Andrew M., Narayan, Rupa, Burke, Meghan E., Foster, Julia, Dal Cin, Paola, Maus, Marcela V., Fathi, Amir T., Hock, Hanno
Wydane w Blood Adv (2020)

Defining the role of syndecan-4 in mechanotransduction using surface-modification approaches

od Bellin, Robert M., Kubicek, James D., Frigault, Matthew J., Kamien, Andrew J., Steward, Robert L., Barnes, Hillary M., DiGiacomo, Michael B., Duncan, Luke J., Edgerly, Christina K., Morse, Elizabeth M., Park, Chan Young, Fredberg, Jeffrey J., Cheng, Chao-Min, LeDuc, Philip R.
Wydane 2009

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma

od Choi, Bryan D., Yu, Xiaoling, Castano, Ana P., Darr, Henia, Henderson, Daniel B., Bouffard, Amanda A., Larson, Rebecca C., Scarfò, Irene, Bailey, Stefanie R., Gerhard, Genevieve M., Frigault, Matthew J., Leick, Mark B., Schmidts, Andrea, Sagert, Jason G., Curry, William T., Carter, Bob S., Maus, Marcela V.
Wydane w J Immunother Cancer (2019)

Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources

od Schmidts, Andrea, Marsh, Leah C, Srivastava, Ambike A, Bouffard, Amanda A, Boroughs, Angela C, Scarfò, Irene, Larson, Rebecca C, Bedoya, Felipe, Choi, Bryan D, Frigault, Matthew J, Bailey, Stefanie R, Leick, Mark B, Vatsa, Sonika, Kann, Michael C, Prew, Michelle S, Kleinstiver, Benjamin P, Joung, J Keith, Maus, Marcela V
Wydane w J Immunother Cancer (2020)

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells

od Frigault, Matthew J, Lee, Jihyun, Basil, Maria Ciocca, Carpenito, Carmine, Motohashi, Shinichiro, Scholler, John, Kawalekar, Omkar U., Guedan, Sonia, McGettigan, Shannon E., Posey, Avery D., Ang, Sonny, Cooper, Laurence J. N., Platt, Jesse M., Johnson, F. Brad, Paulos, Chrystal M, Zhao, Yangbing, Kalos, Michael, Milone, Michael C., June, Carl H.
Wydane w Cancer Immunol Res (2015)

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma

od Schmidts, Andrea, Ormhøj, Maria, Choi, Bryan D., Taylor, Allison O., Bouffard, Amanda A., Scarfò, Irene, Larson, Rebecca C., Frigault, Matthew J., Gallagher, Kathleen, Castano, Ana P., Riley, Lauren S., Cabral, Maria L., Boroughs, Angela C., Velasco Cárdenas, Rubí M.-H., Schamel, Wolfgang, Zhou, Jing, Mackay, Sean, Tai, Yu-Tzu, Anderson, Kenneth C., Maus, Marcela V.
Wydane w Blood Adv (2019)

Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19

od Ormhøj, Maria, Scarfò, Irene, Cabral, Maria L., Bailey, Stefanie R., Lorrey, Selena J., Bouffard, Amanda A., Castano, Ana P., Larson, Rebecca C., Riley, Lauren S., Schmidts, Andrea, Choi, Bryan D., Andersen, Rikke S., Cédile, Oriane, Nyvold, Charlotte G., Christensen, Jacob H., Gjerstorff, Morten F., Ditzel, Henrik J., Weinstock, David M., Barington, Torben, Frigault, Matthew J., Maus, Marcela V.
Wydane w Clin Cancer Res (2019)